Advertisements



We are Sorry, This Page doesn't Exist


Alnylam reports updated "positive" results from Phase 1/2 study of lumasiran

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 4th, 2018

Pfizer"s Skin Disease Candidates Positive in Mid-Stage Study

Pfizer's (PFE) JAK inhibitor candidates -- PF-06651600 and PF-06700841 -- demonstrate improvements in moderate to severe alopecia areata patients in a phase II study. Pfizer Inc. PFE announced positive top-line data from a phase IIa.....»»

Category: personnelSource: nytSep 17th, 2018

Bluebird Bio presents updated data on Phase 2 Starbeam study of Lenti-D

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallSep 5th, 2018

Catalyst Biosciences announces updated data from Phase 2/3 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 15th, 2018

Anika Reports Top Line Data from CINGAL Study, Shares Slump

Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee. Sha.....»»

Category: smallbizSource: nytJun 21st, 2018

TG Therapeutics reports updated results from ongoing ublituximab Phase 2 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 18th, 2018

Bluebird Bio reports interim data from Phase 1 HGB-206 study of LentiGlobin

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 15th, 2018

Nightstar Therapeutics Reports First Quarter 2018 Financial Results and Acceleration of Preliminary NSR-RPGR Readout to Third Quarter 2018

Preliminary data from dose escalation study in the Phase 1/2 XIRIUS trial for X-Linked Retinitis Pigm.....»»

Category: earningsSource: benzingaJun 6th, 2018

Deciphera reports updated interim phase 1 clinical study results with DCC-2618

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 3rd, 2018

Teva reports publication of Phase III HALO study data in JAMA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 15th, 2018

Intercept Reports Phase III Sub-Study Liver Biopsy Data

Intercept (ICPT) announces data from the POISE biopsy sub-study which showed that treatment with obeticholic acid leads to the reversal or stabilization of fibrosis/cirrhosis in patien.....»»

Category: worldSource: nytApr 16th, 2018

Deciphera reports updated data from ongoing Phase 1 DCC-2618 trial

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Eiger BioPharmaceuticals reports results from Phase 2 ULTRA study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 16th, 2018

Roche Announces Positive Data on Breast Cancer Drug Kadcyla

Roche's (RHHBY) breast cancer drug Kadcyla, in a late-stage study in patients suffering from HER2-positive eBCmet, met its goal. Roche RHHBY announced encouraging results from a phase III st.....»»

Category: smallbizSource: nytOct 16th, 2018

Cellect Biotechnology reports safety data from Phase I/II trial of ApoGraft

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 15th, 2018

Bristol-Myers reports Phase 3 CheckMate-331 study does not meet primary endpoint

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 12th, 2018

Bristol-Myers reports Phase 3 CheckMate-331 study does not meet primary endpoint

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 12th, 2018

BeiGene presents updated Phase 1 data on zanubrutinib

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 12th, 2018

J&J"s Stelara Succeeds in Phase III Ulcerative Colitis Study

J&J's (JNJ) Stelara induces clinical remission and response in ulcerative colitis patients who had failed prior therapy, per data from a phase III study. Johnson & Johnson JNJ announce.....»»

Category: smallbizSource: nytOct 10th, 2018

Pluristem publishes PLX-PAD data, to enroll more patients for Phase 3 study

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 10th, 2018